[Multimodality treatment in high-risk and very high-risk prostate cancer: outcomes from international phase III randomized controlled trials]. - Mathier E; Heusel A; Shelan M (Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2022)